JCO:派姆单抗一线疗法治疗转移性NSCLC患者的5年预后明显优于化疗!

2021-04-20 MedSci原创 MedSci原创

派姆单抗作为一线治疗方案用于PD-L1肿瘤比例得分≥50%的转移性NSCLC患者,相比化疗可提供持久的具有临床意义的长期OS效益

从历史上看,尽管使用了铂类药物化疗,但晚期非小细胞肺癌(NSCLC)患者的预后仍较差。对于发生了远处转移的患者,全球5年生存率相对较低,2010年-2016年期间美国晚期NSCLC患者的5年生存率也仅有6.9%。

KEYNOTE-024研究是一项开放标签、随机对照的临床试验,对比了派姆单抗和以铂类为基础的化疗用于既往未治疗过的PD-L1肿瘤比例得分≥50%且不携带EGFR或ALK敏感性变异的NSCLC患者的疗效,既往分析显示派姆单抗可显著延长患者的无进展存活期(PFS)和总体存活期(OS)

本文报告了该III期试验的第一个5年随访结果

在该试验中,受试患者按1:1被随机分至派姆单抗组(200 mg,1次/3周,持续35个疗程)或铂类为基础的化疗组。化疗组患者病情进展后可交叉至派姆单抗组。主要终点是PFS,次要终点是OS。

共招募了305位患者:154位分至派姆单抗组,151位分至了化疗组。从随机化分组至截止日期(2020年6月1日)的中位随访时间为59.9个月。

两组的OS和PFS的Kaplan-Meier评估

在初始分至化疗组的患者中,有99位随后接受了抗PD-1或抗PD-L1治疗,有效交叉率为66.0%派姆单抗组和化疗组的中位OS分别为26.3个月和13.4个月(风险比 0.62,95% CI 0.48-0.81)。派姆单抗组和化疗组的5年OS率的Kaplan-Meier评估分别为31.9%和16.3%。

39位患者接受了35个疗程的派姆单抗治疗(约用时2年),其中82.1%的患者在截止随访日期时仍存活在世(约5年)。随着治疗暴露时间的延长,毒性未见增加。

综上,派姆单抗作为一线治疗方案用于PD-L1肿瘤比例得分≥50%的转移性NSCLC患者,相比化疗可提供持久的具有临床意义的长期OS效益

原始出处:

Reck Martin,Rodríguez-Abreu Delvys,Robinson Andrew G et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.[J] .J Clin Oncol, 2021, undefined: JCO2100174.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1723667, encodeId=a7c51e2366728, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93401, encryptionId=02ef93401bb, topicName=转移性NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=230533519197, createdName=changhe724, createdTime=Thu Feb 17 04:14:22 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069009, encodeId=42c9206900904, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jun 24 18:14:22 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891650, encodeId=23391891650a2, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 20 17:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959284, encodeId=b2a2959284d2, content=派姆单抗可增加患者OS, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 08:33:03 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253469, encodeId=a7a61253469cf, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386746, encodeId=46ef1386e46e5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410865, encodeId=116b14108651d, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959062, encodeId=f8eb9590621c, content=更合适的患者,更惊喜的疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Wed Apr 21 15:22:31 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958875, encodeId=63ad9588e590, content=评论, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/7c5c53fbde0e4181bbfe9fa9330b16e1/aaa7301f2e7f488faff67f9f31895373.jpg, createdBy=4d9f5480726, createdName=huhuanyi, createdTime=Tue Apr 20 21:22:02 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025961, encodeId=62dc10259616a, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Tue Apr 20 20:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1723667, encodeId=a7c51e2366728, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93401, encryptionId=02ef93401bb, topicName=转移性NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=230533519197, createdName=changhe724, createdTime=Thu Feb 17 04:14:22 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069009, encodeId=42c9206900904, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jun 24 18:14:22 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891650, encodeId=23391891650a2, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 20 17:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959284, encodeId=b2a2959284d2, content=派姆单抗可增加患者OS, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 08:33:03 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253469, encodeId=a7a61253469cf, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386746, encodeId=46ef1386e46e5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410865, encodeId=116b14108651d, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959062, encodeId=f8eb9590621c, content=更合适的患者,更惊喜的疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Wed Apr 21 15:22:31 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958875, encodeId=63ad9588e590, content=评论, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/7c5c53fbde0e4181bbfe9fa9330b16e1/aaa7301f2e7f488faff67f9f31895373.jpg, createdBy=4d9f5480726, createdName=huhuanyi, createdTime=Tue Apr 20 21:22:02 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025961, encodeId=62dc10259616a, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Tue Apr 20 20:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
    2021-06-24 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1723667, encodeId=a7c51e2366728, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93401, encryptionId=02ef93401bb, topicName=转移性NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=230533519197, createdName=changhe724, createdTime=Thu Feb 17 04:14:22 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069009, encodeId=42c9206900904, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jun 24 18:14:22 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891650, encodeId=23391891650a2, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 20 17:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959284, encodeId=b2a2959284d2, content=派姆单抗可增加患者OS, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 08:33:03 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253469, encodeId=a7a61253469cf, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386746, encodeId=46ef1386e46e5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410865, encodeId=116b14108651d, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959062, encodeId=f8eb9590621c, content=更合适的患者,更惊喜的疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Wed Apr 21 15:22:31 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958875, encodeId=63ad9588e590, content=评论, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/7c5c53fbde0e4181bbfe9fa9330b16e1/aaa7301f2e7f488faff67f9f31895373.jpg, createdBy=4d9f5480726, createdName=huhuanyi, createdTime=Tue Apr 20 21:22:02 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025961, encodeId=62dc10259616a, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Tue Apr 20 20:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
    2021-04-20 lidong40
  4. [GetPortalCommentsPageByObjectIdResponse(id=1723667, encodeId=a7c51e2366728, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93401, encryptionId=02ef93401bb, topicName=转移性NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=230533519197, createdName=changhe724, createdTime=Thu Feb 17 04:14:22 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069009, encodeId=42c9206900904, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jun 24 18:14:22 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891650, encodeId=23391891650a2, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 20 17:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959284, encodeId=b2a2959284d2, content=派姆单抗可增加患者OS, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 08:33:03 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253469, encodeId=a7a61253469cf, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386746, encodeId=46ef1386e46e5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410865, encodeId=116b14108651d, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959062, encodeId=f8eb9590621c, content=更合适的患者,更惊喜的疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Wed Apr 21 15:22:31 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958875, encodeId=63ad9588e590, content=评论, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/7c5c53fbde0e4181bbfe9fa9330b16e1/aaa7301f2e7f488faff67f9f31895373.jpg, createdBy=4d9f5480726, createdName=huhuanyi, createdTime=Tue Apr 20 21:22:02 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025961, encodeId=62dc10259616a, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Tue Apr 20 20:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
    2021-04-22 科研科研科研

    派姆单抗可增加患者OS

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1723667, encodeId=a7c51e2366728, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93401, encryptionId=02ef93401bb, topicName=转移性NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=230533519197, createdName=changhe724, createdTime=Thu Feb 17 04:14:22 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069009, encodeId=42c9206900904, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jun 24 18:14:22 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891650, encodeId=23391891650a2, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 20 17:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959284, encodeId=b2a2959284d2, content=派姆单抗可增加患者OS, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 08:33:03 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253469, encodeId=a7a61253469cf, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386746, encodeId=46ef1386e46e5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410865, encodeId=116b14108651d, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959062, encodeId=f8eb9590621c, content=更合适的患者,更惊喜的疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Wed Apr 21 15:22:31 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958875, encodeId=63ad9588e590, content=评论, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/7c5c53fbde0e4181bbfe9fa9330b16e1/aaa7301f2e7f488faff67f9f31895373.jpg, createdBy=4d9f5480726, createdName=huhuanyi, createdTime=Tue Apr 20 21:22:02 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025961, encodeId=62dc10259616a, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Tue Apr 20 20:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1723667, encodeId=a7c51e2366728, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93401, encryptionId=02ef93401bb, topicName=转移性NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=230533519197, createdName=changhe724, createdTime=Thu Feb 17 04:14:22 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069009, encodeId=42c9206900904, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jun 24 18:14:22 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891650, encodeId=23391891650a2, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 20 17:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959284, encodeId=b2a2959284d2, content=派姆单抗可增加患者OS, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 08:33:03 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253469, encodeId=a7a61253469cf, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386746, encodeId=46ef1386e46e5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410865, encodeId=116b14108651d, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959062, encodeId=f8eb9590621c, content=更合适的患者,更惊喜的疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Wed Apr 21 15:22:31 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958875, encodeId=63ad9588e590, content=评论, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/7c5c53fbde0e4181bbfe9fa9330b16e1/aaa7301f2e7f488faff67f9f31895373.jpg, createdBy=4d9f5480726, createdName=huhuanyi, createdTime=Tue Apr 20 21:22:02 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025961, encodeId=62dc10259616a, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Tue Apr 20 20:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1723667, encodeId=a7c51e2366728, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93401, encryptionId=02ef93401bb, topicName=转移性NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=230533519197, createdName=changhe724, createdTime=Thu Feb 17 04:14:22 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069009, encodeId=42c9206900904, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jun 24 18:14:22 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891650, encodeId=23391891650a2, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 20 17:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959284, encodeId=b2a2959284d2, content=派姆单抗可增加患者OS, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 08:33:03 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253469, encodeId=a7a61253469cf, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386746, encodeId=46ef1386e46e5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410865, encodeId=116b14108651d, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959062, encodeId=f8eb9590621c, content=更合适的患者,更惊喜的疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Wed Apr 21 15:22:31 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958875, encodeId=63ad9588e590, content=评论, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/7c5c53fbde0e4181bbfe9fa9330b16e1/aaa7301f2e7f488faff67f9f31895373.jpg, createdBy=4d9f5480726, createdName=huhuanyi, createdTime=Tue Apr 20 21:22:02 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025961, encodeId=62dc10259616a, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Tue Apr 20 20:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1723667, encodeId=a7c51e2366728, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93401, encryptionId=02ef93401bb, topicName=转移性NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=230533519197, createdName=changhe724, createdTime=Thu Feb 17 04:14:22 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069009, encodeId=42c9206900904, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jun 24 18:14:22 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891650, encodeId=23391891650a2, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 20 17:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959284, encodeId=b2a2959284d2, content=派姆单抗可增加患者OS, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 08:33:03 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253469, encodeId=a7a61253469cf, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386746, encodeId=46ef1386e46e5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410865, encodeId=116b14108651d, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959062, encodeId=f8eb9590621c, content=更合适的患者,更惊喜的疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Wed Apr 21 15:22:31 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958875, encodeId=63ad9588e590, content=评论, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/7c5c53fbde0e4181bbfe9fa9330b16e1/aaa7301f2e7f488faff67f9f31895373.jpg, createdBy=4d9f5480726, createdName=huhuanyi, createdTime=Tue Apr 20 21:22:02 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025961, encodeId=62dc10259616a, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Tue Apr 20 20:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
    2021-04-21 JZ Yang

    更合适的患者,更惊喜的疗效

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1723667, encodeId=a7c51e2366728, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93401, encryptionId=02ef93401bb, topicName=转移性NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=230533519197, createdName=changhe724, createdTime=Thu Feb 17 04:14:22 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069009, encodeId=42c9206900904, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jun 24 18:14:22 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891650, encodeId=23391891650a2, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 20 17:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959284, encodeId=b2a2959284d2, content=派姆单抗可增加患者OS, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 08:33:03 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253469, encodeId=a7a61253469cf, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386746, encodeId=46ef1386e46e5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410865, encodeId=116b14108651d, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959062, encodeId=f8eb9590621c, content=更合适的患者,更惊喜的疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Wed Apr 21 15:22:31 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958875, encodeId=63ad9588e590, content=评论, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/7c5c53fbde0e4181bbfe9fa9330b16e1/aaa7301f2e7f488faff67f9f31895373.jpg, createdBy=4d9f5480726, createdName=huhuanyi, createdTime=Tue Apr 20 21:22:02 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025961, encodeId=62dc10259616a, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Tue Apr 20 20:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
    2021-04-20 huhuanyi

    评论

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1723667, encodeId=a7c51e2366728, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93401, encryptionId=02ef93401bb, topicName=转移性NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=230533519197, createdName=changhe724, createdTime=Thu Feb 17 04:14:22 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069009, encodeId=42c9206900904, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jun 24 18:14:22 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891650, encodeId=23391891650a2, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 20 17:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959284, encodeId=b2a2959284d2, content=派姆单抗可增加患者OS, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 08:33:03 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253469, encodeId=a7a61253469cf, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386746, encodeId=46ef1386e46e5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410865, encodeId=116b14108651d, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Thu Apr 22 08:14:22 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959062, encodeId=f8eb9590621c, content=更合适的患者,更惊喜的疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Wed Apr 21 15:22:31 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958875, encodeId=63ad9588e590, content=评论, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/7c5c53fbde0e4181bbfe9fa9330b16e1/aaa7301f2e7f488faff67f9f31895373.jpg, createdBy=4d9f5480726, createdName=huhuanyi, createdTime=Tue Apr 20 21:22:02 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025961, encodeId=62dc10259616a, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Tue Apr 20 20:14:22 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
    2021-04-20 健康达人

    肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!

    0

相关资讯

奥希替尼为EGFR突变阳性伴脑膜转移NSCLC患者带来显著获益

2019年4月10—13日,2019年欧洲肺癌大会在瑞士日内瓦隆重召开,本次会议聚集了来自全球肺癌领域的知名专家,众多最新临床研究结果在本次会议中公布。中枢神经系统转移是EGFR突变阳性晚期非小细胞肺癌常见的远处转移,与第一代、第二代EGFR-TKI相比,奥希替尼能更好地穿透血脑屏障,既往的研究显示奥希替尼在脑膜转移患者中显示出良好的抗肿瘤活性,为此研究者回顾性地分析了AURA系列研究中合并脑膜转

吡咯替尼或为HER2突变NSCLC患者提供全新治疗选择

第55届美国临床肿瘤学会年会(ASCO?)已落下帷幕。作为临床肿瘤学界最负盛名的国际学术交流平台,来自全世界共约32,000名肿瘤学家,汇聚于芝加哥,分享了近一年来肿瘤学领域的最新进展,交流诊治经验。年会期间,非小细胞肺癌(NSCLC)领域多项新药研究亮相,其中一项由同济大学附属肺科医院周彩存教授作为主要研究者(PI)应用吡咯替尼治疗人表皮生长因子2(HER2)突变的晚期NSCLC临床研究在肺癌专

阿帕替尼+卡瑞利珠单抗联合出击,为NSCLC患者带来新希望

在刚刚结束的第55届美国临床肿瘤学会(ASCO?)年会上,一项由同济大学附属肺科医院周彩存教授作为主要研究者(PI),应用阿帕替尼联合免疫检查点抑制剂治疗晚期非小细胞肺癌(NSCLC)的临床研究结果在肺癌专场上公布。记者在第一时间采访了周彩存教授,请他向广大读者介绍该项研究的详细情况。患者的福音——晚期NSCLC一线治疗或进入无化疗时代

贝达药业埃克替尼第3项适应症申报上市,用于NSCLC患者术后辅助治疗

9月21日,贝达药业发布公告称其盐酸埃克替尼片(商品名:凯美纳)用于术后辅助治疗的新适应症上市许可申请已获国家药品监督管理局受理。

晚期NSCLC患者治疗的新选择与新希望

国家食品药品监督管理总局(CFDA)已正式批准盐酸安罗替尼用于晚期非小细胞肺癌(NSCLC)患者的三线治疗,掀开了晚期非小细胞肺癌(NSCLC)治疗新篇章.特别邀请到江苏省人民医院卢凯华教授与南京鼓楼医院王立峰教授共同探讨安罗替尼上市几个月以来的临床应用情况与未来的应用前景。

术中先处理动脉还是静脉对NSCLC患者循环肿瘤细胞及生存的影响(IF暂无)

SCI10 May 2019Effect of Vein-First vs Artery-First Surgical Technique on Circulating Tumor Cells and Survival in Patients With Non–Small Cell Lung CancerWei S, Guo C, He J, et al. Effect of Vein-Fir